Showing results (491-500 of 543) with videos related to

Sort By:
Pageof 55
Breast Cancer Research and Treatment|September 3, 2010
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapyAlastair M Thompson, Andrea Johnson, Philip Quinlan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.
Ecology and Evolution|March 10, 2026
Survival of a Long-Lived Avian Scavenger: Implications of Age, Season, and Landscape Composition for Mortality RiskSpencer B Hudson, Eric A Tillman, Marian L Wahl, et al.
Blood|November 15, 2021
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosisAdi Zoref-Lorenz, Jun Murakami, Liron Hofstetter, et al.
Bone Marrow Transplantation|September 22, 2021
A prospective pilot study of a novel alemtuzumab target concentration intervention strategyDanielle E Arnold, Chie Emoto, Tsuyoshi Fukuda, et al.
The New England Journal of Medicine|May 7, 2020
Emapalumab in Children with Primary Hemophagocytic LymphohistiocytosisFranco Locatelli, Michael B Jordan, Carl Allen, et al.
Blood|July 24, 2024
Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisitedJan-Inge Henter, Elena Sieni, Julia Eriksson, et al.
Blood|April 18, 2019
Recommendations for the management of hemophagocytic lymphohistiocytosis in adultsPaul La Rosée, AnnaCarin Horne, Melissa Hines, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab RegimenRebecca A Marsh, Marepalli B Rao, Aharon Gefen, et al.
Elife|September 16, 2016
TP53 drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Pageof 55